Four Genes Identified that Influence Levels of ‘Bad’ Cholesterol; May Be New Targets for Treatments to Reduce Heart Disease Risk
SAN ANTONIO, May 15, 2013 - Scientists at the Texas Biomedical Research Institute have identified four ...
By Scott Bailey, San Antonio Business Journal The University of Texas Health Science Center at San Antonio ...
SAN ANTONIO, Texas, July 31, 2012 - GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy. The Phase II study is anticipated to be conducted at up to six sites in the United States and the United Kingdom, and is expected to involve the aggregate enrollment of up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant prostate cancer. Commencement of the trial and enrollment of patients is pending approval from the respective Institutional Review Boards at the participating sites.
"We are excited that G-202 will be delivered to patients who have prostate cancer, where we expect its ability to target slow-growing cancer cells should be particularly effective," said Samuel R. Denmeade, MD, GenSpera's Chief Clinical Advisor and Co-Founder. "We have spent two decades developing a ‘molecular grenade' that is designed to be activated only within the tumor. It is gratifying to see it progress to advanced clinical studies." Dr. Denmeade is also Professor of Oncology, Urology, Pharmacology, and Molecular Sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
"We are pleased that G-202 has received clearance from the FDA to initiate our Phase II study in prostate cancer. The trial, which is anticipated to be conducted at multiple sites in the United States and the United Kingdom, is part of our corporate strategy to gain entry into the international oncology community early in the clinical development of G-202," said Craig Dionne, PhD, GenSpera CEO and President.
GenSpera, Inc. is a development-stage oncology company focused on therapeutics that have the potential to deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that appears to release the drug only within the tumor. Unlike standard cancer drugs, thapsigargin has been shown to kill cells independently of their division rate, thus providing the potential for an effective approach to kill all fast- and slow-growing cancers and cancer stem cells.
GenSpera has completed a Phase Ia dose-escalation safety and tolerability study with its lead drug, G-202, at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, the University of Wisconsin Carbone Cancer Center, and the Cancer Therapy and Research Center at the University of Texas Health Science Center in San Antonio. The study has continued into a Phase Ib dose refinement study at the same clinical sites. G-202 has been cleared for initiation of a multi-center Phase II trial in patients with chemotherapy-naïve, metastatic castrate-resistant prostate cancer. GenSpera expects to initiate multiple Phase II trials of G-202 in several different types of cancer. The initiation of the Phase II trials at each site is subject to the approval of their respective Institutional Review Boards.
GenSpera's pipeline of drugs also includes G-114, G-115 and G-301, all of which directly target prostate cancer.
For more information, please visit the Company's website: www.genspera.com .
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.